Stat of the Week: October Deal Volume +9%
After a few months of slow going, healthcare deal volume revved up in October. Although it’s the start of the typically busy fourth quarter, we’ve learned not to expect past performance to indicate future results. Preliminary data shows 130 transactions were announced, up 9% compared with the 119 deals announced in both September 2017 and October 2016. Deal value was comparatively strong, as well. The $12.1 billion reported for October 2017 is 4% higher than the previous month ($11.7 billion), but 8% lower than the same month a year ago ($13.2 billion). Three deals came with $1 billion-plus prices and a combined total of $8.5 billion, or 70% of the month’s spending. By contrast, September... Read More »
Deal of the Week: Novartis/AAAP
Novartis AG (NYSE: NVS) has spent most of 2017 buying up licenses to preclinical candidates. In the first 10 months of this year, it spent approximately $225 million in disclosed upfront payments. But the Swiss drugmaker just spent $3.9 billion for a more established drug product targeting neuroendocrine tumors. On October 30, 2017, Novartis acquired Advanced Accelerator Applications S.A. (NASDAQ: AAAP), a French radiopharmaceutical company that develops, produces and commercializes molecular nuclear medicines including Lutathera® (177Lu-DOTATATE), a first-in-class RLT product for neuroendocrine tumors (NETs). The radiopharmaceutical was approved in Europe last month for the treatment of... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
